Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models
Open Access
- 20 August 2026
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8730
Abstract
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder mediated by autoantibodies targeting the nicotinic acetylcholine receptor (nAChR), which can lead to severe disability and life-threatening crises. Current therapies rely on broad immunosuppression and fail to achieve sustained remission in the majority of patients. Here, we report the development of AChR chimeric autoantibody receptor (CAAR) T cells engineered to selectively eliminate autoreactive B cells producing anti-AChR autoantibodies. T cells were co-transduced with CAARs expressing extracellular domains of the AChRα1 or β1 subunits, enabling recognition of a broad range of pathogenic antibodies. AChR CAAR T cells selectively secreted effector cytokines upon activation, and efficiently lysed target cells. In a xenograft mouse model, they depleted pathogenic B cell lines and reduced autoantibody levels in the circulation and at the neuromuscular junction. These findings establish AChR CAAR T cells as a precision immunotherapy with the potential to achieve durable remission in refractory MG.Keywords
This publication has 43 references indexed in Scilit:
- Human cerebrospinal fluid monoclonalN-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesisBrain, 2016
- Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune diseaseScience, 2016
- Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis PatientsPLOS ONE, 2014
- Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravisJournal of Neurology, Neurosurgery & Psychiatry, 2012
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cellsBlood, 2011
- Isolation and functional characterization of anti-acetylcholine receptor subunit-specific autoantibodies from myasthenic patients: Receptor loss in cell cultureJournal of Neuroimmunology, 2007
- Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor α-subunit. Development of an antigen-specific therapeutic strategyJournal of Neuroimmunology, 2005
- The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodiesMolecular Neurobiology, 1991
- Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravisNeurology, 1989
- Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies.Proceedings of the National Academy of Sciences, 1982